Brind.

Trials for Orocidin are planned at the University of Copenhagen, following Bio-Convert receiving a toxicity waiver from the Danish Medicines Agency.

1 report, 1 independent Updated Jun 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Trials for Orocidin are planned at the University of Copenhagen, following Bio-Convert receiving a toxicity waiver from the Danish Medicines Agency.

Who's involved

What this event is mainly about
University of CopenhagenDanish Medicines Agency

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped